Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 16,003 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide, Fludarabine, G-CSF, Melphalan, Mesna, Rituximab, Tacrolimus, Thiotepa, HPC,A Infusion, CliniMACS, Sirolimus
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
Interventions
monoclonal antibody Ch14.18, isotretinoin, aldesleukin, sargramostim
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Arcadia, California
Terminated Not applicable Interventional Results available

Treatment of Sickle Cell Anemia With Stem Cell Transplant

NCT01350232
Conditions
Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
Interventions
Fludarabine, Cytarabine, Cellular Infusions, Total Body Irradiation, Cyclophosphamide, Bortezomib, Rituximab, Plasmapheresis
Drug · Device · Radiation + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
Fludarabine, Cyclophosphamide, Rituximab, Pentostatin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
11
States / cities
Ocoee, Florida • Terre Haute, Indiana • Westminster, Maryland + 8 more
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Drug
Lead sponsor
Edwin Horwitz
Other
Eligibility
1 Year and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Recruiting Phase 1 Interventional

GAIP ASD Research Study

NCT07622316
Conditions
Autism Spectrum Disorder, Autism, ASD, Autism Spectrum Disorder (ASD)
Interventions
Umbilical Cord Blood-Derived Stem Cells and Exosomes, Glutathione
Biological · Drug
Lead sponsor
Greater Atlanta Integrative Pediatrics
Other
Eligibility
3 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Roswell, Georgia
Completed Not applicable Interventional Results available

Loading Vancomycin Doses in the Emergency Department

NCT01162733
Conditions
Infectious Disease
Interventions
Vancomycin
Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newark, Delaware
Completed Phase 1 Interventional Accepts healthy volunteers

Glucagon Regulation of Glucose Metabolism

NCT04347252
Conditions
Insulin Secretion
Interventions
Glucagon
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Botulinum Toxin on Muscle and Brain Activity

NCT02837185
Conditions
Cervical Dystonia, Primary
Interventions
Botulinum Toxin injection, Physiological measures
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Breast Cancer
Interventions
therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Ipilimumab, Nivolumab
Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Rochester, Minnesota + 2 more
Conditions
Melanoma
Interventions
trametinib, nab-paclitaxel
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
alemtuzumab
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
69
States / cities
Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
Conditions
Low Grade Glioma, High Grade Glioma
Interventions
Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 26 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York
Conditions
Solid Tumor, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Vorolanib, Nivolumab, Pembrolizumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
Conditions
Brain Injuries, Growth Hormone Deficiency Dwarfism
Interventions
somatropin
Genetic
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Pittsburgh, Pennsylvania • El Paso, Texas • Salt Lake City, Utah + 1 more
Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
Interventions
Bevacizumab, Fluorouracil, Leucovorin, Oxaliplatin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
910
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 578 more
Conditions
Type 1 Diabetes Mellitus
Interventions
Bihormonal Bionic Pancreas, Insulin Only Bionic Pancreas, Glucagon, Placebo
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Recurrent Respiratory Papillomatosis
Interventions
Avastin® (bevacizumab), Saline
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 2 Interventional

Pan Tumor Rollover Study

NCT03899155
Conditions
Cancer
Interventions
Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
59
States / cities
Huntsville, Alabama • Tucson, Arizona • Lynwood, California + 46 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
bevacizumab with chemotherapy, Pleur-XTM catheter placement
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Liver Cancer, Advanced Solid Tumors
Interventions
Fluorouracil, Avastin, Leucovorin, Oxaliplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas